Medical University of Bialystok
Bialystok, 15-089, Poland
NCT Number: NCT07625319
This study evaluated differences in serum concentrations of selected gut hormones (GLP-1, GIP, cholecystokinin, and omentin) among individuals with varying nutritional status following a standardized meal.
A total of 80 adults were enrolled and stratified by BMI. Fasting and postprandial hormone levels were assessed at multiple time points.
Additionally, dietary habits, physical activity, body composition, and resting energy expenditure were evaluated to explore their association with hormonal responses.
Looking for future studies?
Notify Me40 year–60 year
All sexes
Interventional
Not applicable
Bialystok, 15-089, Poland
Stage I
A total of 80 participants (women and men) aged 40-60 years who voluntarily consent to participate in the study will be enrolled:
Control group (G0): 20 participants (10 women, 10 men) with normal body weight - BMI 18.5-24.9 kg/m² Study group I (G1): 20 participants (10 women, 10 men) with overweight - BMI 25.0-29.9 kg/m² Study group II (G2): 20 participants (10 women, 10 men) with class I obesity - BMI 30.0-34.9 kg/m² Study group III (G3): 20 participants (10 women, 10 men) with class II obesity - BMI 35.0-39.9 kg/m²
Participants will complete a questionnaire-based survey consisting of the following standardized instruments:
Quantitative assessment of dietary intake will be performed using a 24-hour dietary recall collected over three days (two weekdays and one weekend day).
Body composition analysis will also be performed using dual-energy X-ray absorptiometry (DEXA), which utilizes dual-energy X-ray beams. This technique allows assessment of the whole body and individual body segments by dividing body composition into three main compartments: bone mineral content, lean body mass (excluding bone mineral content), and fat mass.
DEXA is considered a valuable tool for body composition assessment in clinical studies, particularly among individuals with overweight and obesity, as it enables more accurate evaluation of body composition and long-term cardiovascular and oncological risk associated with excess body weight.
The method is safe, rapid, and non-invasive due to the very low radiation dose. Radiation exposure during the examination is approximately 0.001 mSv. The examination is performed in the supine position.
Stage II
Normocarbohydrate formulation (Nutridrink Standard) Composition of the Standardized Meal - Nutridrink Standard Parameter Per 100 mL Energy 240 kcal Carbohydrates 29.6 g
Stage III
The examination involves analysis of exhaled air composition (oxygen and carbon dioxide concentrations) using specialized equipment (Q-NRG+, COSMED). Measurements will be conducted using sterile disposable mouthpieces and an oxygen mask. Indirect calorimetry is completely safe, painless, and non-invasive. The examination will be performed once.
The obtained results will be subjected to statistical analysis using Statistica 13.3 software (StatSoft Inc.).
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Participants received 187.5 mL of a ready-to-drink oral nutritional supplement (Nutridrink Protein).
Time frame: 24 months (analyzes were performed throughout the study period).
Postprandial changes in serum glucagon-like peptide-1 (GLP-1) (pmol/L).
Time frame: 24 months (analyzes were performed throughout the study period).
Postprandial changes in serum glucose-dependent insulinotropic polypeptide (GIP) (pg/mL).
Time frame: 24 months (analyzes were performed throughout the study period).
Postprandial changes in serum cholecystokinin (pg/mL).
Time frame: 24 months (analyzes were performed throughout the study period).
Postprandial changes in serum omentin (ng/mL).
Time frame: 24 months (analyzes were performed throughout the study period).
Complete blood count assessed from fasting venous blood samples, including hemoglobin (g/dl).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Fasting glucose concentration (mg/dL)
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Fasting insulin concentration (µIU/mL)
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Lipid profile parameters: total cholesterol (mg/dL).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. C-reactive protein concentration (mg/L)
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Alanine aminotransferase activity (U/L).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Aspartate aminotransferase activity (U/L).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Creatinine concentration (mg/dL).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Uric acid concentration (mg/dL).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Lipid profile parameters: HDL cholesterol.
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Lipid profile parameters: triglycerides (mg/dL).
Time frame: 24 months (analyzes were performed throughout the study period).
Laboratory parameters assessed from fasting blood samples. Lipid profile parameters: LDL cholesterol (mg/dl).
Time frame: 24 months (analyzes were performed throughout the study period).
Assessment of total fat mass (kg).
Time frame: 24 months (analyzes were performed throughout the study period).
Assessment of visceral adipose tissue (cm³).
Time frame: 24 months (analyzes were performed throughout the study period).
Assessment of lean body mass (kg).
Time frame: 24 months (analyzes were performed throughout the study period).
Differences in physical activity levels between participants with normal body weight (BMI 18.5-24.9 kg/m²), overweight (BMI 25.0-29.9 kg/m²), obesity I (BMI 30.0-34.9 kg/m²) and obesity II (≥35 kg/m²) assessed using the IPAQ questionnaire.
Time frame: 24 months (analyzes were performed throughout the study period).
Resting Energy Expenditure: REE was measured using indirect calorimetry (Q-NRG+, COSMED).
Time frame: 24 months (analyzes were performed throughout the study period).
Differences in dietary habits between participants with normal body weight (BMI 18.5-24.9 kg/m²), overweight (BMI 25.0-29.9 kg/m²), obesity I (BMI ≥30.0-34.9 kg/m²) and obesity II (BMI ≥35.0 kg/m²), assessed using standardized questionnaires including the QEB, TFEQ-R18, and the hunger-satiety scale.
Time frame: 24 months (analyzes were performed throughout the study period).
Quality of life assessed using the World Health Organization Quality of Life questionnaire (WHOQOL-BREF).
Time frame: 24 months (analyzes were performed throughout the study period).
Complete blood count assessed from fasting venous blood samples, including hematocrit (%).
Time frame: 24 months (analyzes were performed throughout the study period).
Complete blood count assessed from fasting venous blood samples, including white blood cell count ×10^3/µL.
Time frame: 24 months (analyzes were performed throughout the study period).
Complete blood count assessed from fasting venous blood samples, including red blood cell count ×10^6/µL.
Time frame: 24 months (analyzes were performed throughout the study period).
Complete blood count assessed from fasting venous blood samples, including platelet count ×10^3/µL.
Medical University of Bialystok
Other
Analysis of Differences in Serum Concentrations of Selected Gut Hormones in Patients With Varying Nutritional Status Following Consumption of a Standardized Meal.
Acronym: GUT-NUT
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05742165
Behavior, Body Weight
New York, United States
View Trial DetailsNCT05882045
Body Weight, Cardiovascular Diseases
Phoenix, Arizona, United States
View Trial DetailsNCT05929079
Apnea, Body Weight
Anniston, Alabama, United States
View Trial DetailsNCT00342732
Body Weight, Nutrition Disorders
Phoenix, Arizona, United States
View Trial Details